Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

BACKGROUND: The sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAF(V600) mutant melanoma is limited primarily by the development of acquired resistance leading to tumor progression. Clinical trials are in progress using MEK inhibitors following disea...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Atefi, Mohammad, von Euw, Erika, Attar, Narsis, Ng, Charles, Chu, Connie, Guo, Deliang, Nazarian, Ramin, Chmielowski, Bartosz, Glaspy, John A., Comin-Anduix, Begonya, Mischel, Paul S., Lo, Roger S., Ribas, Antoni
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2011
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3237573/
https://ncbi.nlm.nih.gov/pubmed/22194965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0028973
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items